Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold reduction (hazard ratio = 0.24 [95% confidence interval: 0.13, 0 ...
AN2 Therapeutics (ANTX) announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis respiratory domain patient reported outcome ...
On Thursday, Omeros Corporation (NASDAQ:OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab. Omeros is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback